Compare Elastic NV (ESTC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Mesoblast Limited — how do they compare? Elastic NV trades at $95.26 (market cap $10.00B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Elastic NV is far larger — about 5.7× Mesoblast Limited's market cap, and Elastic NV is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Mesoblast Limited for 14 Days on average.
| ESTC | MESO | |
|---|---|---|
Market Cap | $10.00B | $1.75B |
Volume | 1,610,337 | 239,027 |
Sector | Technology | Health |
52-Week High | $99.91 | $20.96 |
52-Week Low | $43.30 | $13.19 |
Typical Hold Time | 10 Days | 14 Days |
Enterprise Value | $9.14B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $93.10, down 1.59% today but maintains strong technical momentum with a bullish moving average signal. The company shows robust revenue growth with Q2 2026 EPS beating expectations at $0.70 versus $0.584, and analyst consensus remains strongly positive with 22 buy ratings and no sell recommendations. Recent product launches including AI-powered metrics and serverless vector database enhancements demonstrate ongoing innovation.
The outlook remains favorable with projected revenue growth to $1.8B in 2026 and net income turning positive to $376M. Key risks include high valuation multiples and competitive pressures in the enterprise software space. The consensus price target of $79.50 suggests potential downside from current levels despite strong fundamentals.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
